Fit tech

Houston fitness guru takes her expertise mobile with new app

Lizzie DeLacy, founder of DeLacy Wellness, launched a new platform called Bodypeace offering wellness and exercise tips through the app. Courtesy of DeLacy Wellness

As time spent on mobile devices stretches longer and attention spans get shorter, a Houstonian thinks she has a solution to combine personal technology and a healthy lifestyle.

Lizzie DeLacy, founder of DeLacy Wellness, has launched a new app called Bodypeace that offers workout sessions, recipes, and tips for a healthier lifestyle, but in a different way than consumers might be used to.

"Rather than focusing on really long sessions, though we have a couple in there, we focus on short 5 minute sessions, so anyone can fit movement into their schedule and lifestyle," DeLacy tells InnovationMap. "Additionally, we break it down by body part focus, because oftentimes people don't know necessarily what exact movement or pose or stretch they might need."

DeLacy worked as a private fitness instructor for years before deciding to create the Bodypeace app to make her coaching and practices accessible to more people. Her goal is to help as many people as possible feel better so they can grow to be the best version of themselves, referring to this concept as "Eventual Energy."

The Bodypeace app, which launched on iTunes and Google Play on July 17, allows users to filter by body part, choosing between an all body session, or focus on a specific spot such as hamstrings, hips, back, shoulders, and more.

"In my experience as a yoga instructor, I saw that these are pain points for a lot of people," says DeLacy.

The app tailors content for the user by asking a series of questions about workout habits, and lifestyle. There is a free trial period for users to explore the app, as well as paid options, $17.99 a month or $119.99 a year.

"The busier people get the less they want to spend time in their cars or pay the fees that are associated with gym memberships, and having the ability to do something from the comfort of your own home or on demand that fits your schedule," says DeLacy. "I think it's really appealing to a lot of people, myself included."

DeLacy shares that many fitness apps out there geared towards getting a six pack or losing weight can be intimidating to those that have never worked out before or have an injury that they're recovering from. She designed her app to be accessible for all fitness levels, ages, and genders.

"The content on Bodypeace is really for the athletes and the 'never-evers' alike," DeLacy tells InnovationMap. "There is a whole group of people that are either new to working out or have never considered it before."

DeLacy founded DeLacy Wellness in 2016, a year after she moved to Houston. DeLacy is a certified yoga instructor and holds a health coaching certification. The company, which is privately funded, has two full-time staff, DeLacy and her partner and COO Jack Martin, two advisory board members, two instructors, and one community contributor.

DeLacy tells InnovationMap that on the community portion of the Bodypeace app, there is a lot of free information available for users to test the content. DeLacy and her team hope to connect wellness content creators and contributors with people who are looking for information to feel and live better.

"We're hoping to create a platform where you're doing movement and you're also going to learn about movement, nutrition, mental health, and other topics dealing with wellness," says DeLacy.


Trending News

Building Houston

 
 

Tvardi Therapeutics Inc. has fresh funds to support its drug's advancement in clinical trials. Photo via Getty Images

A Houston-based clinical-stage biopharmaceutical company has raised millions in its latest round.

Tvardi Therapeutics Inc. closed its $74 million series B funding round led by new investors New York-based Slate Path Capital, Florida-based Palkon Capital, Denver-based ArrowMark Partners, and New York-based 683 Capital, with continued support and participation by existing investors, including Houston-based Sporos Bioventures.

"We are thrilled to move out of stealth mode and partner with this lineup of long-term institutional investors," says Imran Alibhai, CEO at Tvardi. "With this financing we are positioned to advance the clinical development of our small molecule inhibitors of STAT3 into mid-stage trials as well as grow our team."

Through Slate Path Capital's investment, Jamie McNab, partner at the firm, will join Tvardi's board of directors.

"Tvardi is the leader in the field of STAT3 biology and has compelling proof of concept clinical data," McNab says in the release. "I look forward to partnering with the management team to advance Tvardi's mission to develop a new class of breakthrough medicines for cancer, chronic inflammation, and fibrosis."

Tvardi's latest fundraise will go toward supporting the company's products in their mid-stage trials for cancer and fibrosis. According to the release, Tvardi's lead product, TTI-101, is being studied in a Phase 1 trial of patients with advanced solid tumors who have failed all lines of therapy. So far, the drug has been well-received and shown multiple durable radiographic objective responses in the cancer patients treated.

Dr. Keith Flaherty, who is a member of Tvardi's scientific advisory board and professor of medicine at Harvard Medical School, offered his support of the company.

"STAT3 is a compelling and validated target. Beyond its clinical activity, Tvardi's lead molecule, TTI-101, has demonstrated direct downregulation of STAT3 in patients," he says in the release. "As a physician, I am eager to see the potential of Tvardi's molecules in diseases of high unmet medical need where STAT3 is a key driver."

Trending News